Daxor (DXR) Price & Analysis

Compare

92 Followers

DXR Stock Chart & Stats

Day’s Range― - ―

52-Week Range$6.55 - $11.21

Previous CloseN/A

Volume734.00

Average Volume (3M)50.70K

Market Cap

$35.03M

Enterprise Value$38.67M

Total Cash (Recent Filing)$0.00

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)99.3

Beta0.37

Next Earnings

Aug 21, 2025

EPS EstimateN/A

Last Dividend Ex-Date

Jan 05, 2018

Dividend YieldN/A

Share Statistics

EPS (TTM)0.44

Shares Outstanding4,962,245

10 Day Avg. Volume146,099

30 Day Avg. Volume50,696

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap1.10

Enterprise Value/Revenue50.42

Enterprise Value/Gross Profit55.85

Enterprise Value/Ebitda-40.18

Forecast

1Y Price Target

$22.00

Price Target Upside93.32% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Financial PerformanceDaxor reported strong revenue growth of +117% in its blood volume business across leading medical centers in the U.S.

Market StrategyDaxor's acquisition of exclusive rights to manufacture certain products is expected to be cash flow positive and accretive to earnings immediately.

Regulatory ApprovalThe next-gen blood volume analyzer (BVA) from Daxor received FDA 510(k) clearance, which is expected to accelerate its adoption.

Bears Say

Product DevelopmentDaxor is developing a next-generation BVA that is more than three times faster and capable of providing full results at the bedside, with FDA approval expected in 2025.

Regulatory StrategyThe decision to pivot to a single 510(k) submission, rather than a dual CLIA waiver approach, is a prudent regulatory strategy that reduces data burden and accelerates the approval timeline.

Daxor News

Why Is Daxor Stock (DXR) Up 20% Today?

Daxor stock rallied on Thursday after it received clearance from the FDA for its new Blood Volume Analyzer. ...

7d ago

DXR

Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories

Investors looking for all of the hottest stock market stories for Thursday are in the right place! ...

7d ago

AMD

Daxor receives FDA clearance for new BVA system

Daxor (DXR) Corporation announces FDA 510(k) clearance for its patent-pending next-generation rapid, compact, hand-held, lab-based Blood Volume Analyzer,...

7d ago

DXR

Daxor expands BVA technology into three new hospitals

Daxor (DXR) announces the expansion of its blood volume analysis technology into three new hospitals, a testament to...

23d ago

DXR

Daxor’s FDA Clearance and Advancements Propel Buy Rating Amidst Growth Potential

Anthony Vendetti, an analyst from Maxim Group, reiterated the Buy rating on Daxor. The associated price target is...

2d ago

DXR

Daxor Gains FDA Clearance for Blood Volume Analyzer

Daxor ( ($DXR) ) just unveiled an update. Daxor Corporation announced FDA 510(k) clearance for its next-generation Blood...

7d ago

DXR

Daxor Approves Accounting Firm at Annual Meeting

Daxor ( ($DXR) ) has issued an update. Daxor Corporation held its Annual Meeting on June 24, 2025,...

1M ago

DXR

Daxor announces new findings from Duke University on BVA

Daxor (DXR) Corporation announces significant new findings from Duke University Medical Center published in the prestigious American Heart...

3M ago

DXR

Daxor announces expansion of diagnostic solutions into two healthcare systems

Daxor (DXR) announces the expansion of its diagnostic solutions into two additional U.S. healthcare systems, further advancing the...

3M ago

DXR

Daxor announces opening of new BVA program at Florida center

Daxor (DXR) Corporation announces the opening of a new BVA program at a premier Florida healthcare center in...

3M ago

DXR

Daxor announces expansion of BVA capabilities in three new hospitals

Daxor (DXR) Corporation announces significant expansion of its blood volume analysis, BVA, capabilities in three new hospitals. This...

3M ago

DXR

Daxor to showcase blood volume analysis at Cardiovascular Transforum conference

Daxor (DXR) Corporation will be exhibiting at the MedAxiom CV Transforum Spring’25 Conference being held at the Renaissance...

4M ago

DXR

Daxor announces new data at ACC on blood volume analysis

Daxor (DXR) Corporation announced new data presented at the American College of Cardiology, ACC, 74th Annual Scientific Session...

4M ago

DXR

Daxor announces submission of Daxor BVA to FDA

Daxor (DXR) Corporation announces the submission of its next-generation blood volume analyzer – Daxor BVA – to the...

4M ago

DXR

DXR FAQ

What was Daxor Corp’s price range in the past 12 months?

Daxor Corp lowest stock price was $6.55 and its highest was $11.21 in the past 12 months.

What is Daxor Corp’s market cap?

Daxor Corp’s market cap is $35.03M.

When is Daxor Corp’s upcoming earnings report date?

Daxor Corp’s upcoming earnings report date is Aug 21, 2025 which is in 7 days.

How were Daxor Corp’s earnings last quarter?

Daxor Corp released its earnings results on Mar 06, 2025. The company reported $0.439 earnings per share for the quarter, beating the consensus estimate of N/A by $0.439.

Is Daxor Corp overvalued?

According to Wall Street analysts Daxor Corp’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Daxor Corp pay dividends?

Daxor Corp pays a Monthly dividend of $0.03 which represents an annual dividend yield of N/A. See more information on Daxor Corp dividends here

What is Daxor Corp’s EPS estimate?

Daxor Corp’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Daxor Corp have?

Daxor Corp has 4,962,245 shares outstanding.

What happened to Daxor Corp’s price movement after its last earnings report?

Daxor Corp reported an EPS of $0.439 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.96%.

Which hedge fund is a major shareholder of Daxor Corp?

Currently, no hedge funds are holding shares in DXR

Daxor Stock Smart Score

Neutral

Fundamentals

Return on Equity

1.54%

Trailing 12-Months

Asset Growth

5.06%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Daxor Corp

Daxor Corporation (DXR) is a medical instrumentation and biotechnology company that specializes in blood volume analysis technology. The company focuses on advancing healthcare by providing innovative diagnostic tools and services that enhance the understanding and treatment of various medical conditions. Daxor's flagship product, the BVA-100, is an FDA-cleared diagnostic device that measures human blood volume, aiding in the precise assessment of fluid management in patients.

Daxor (DXR) Earnings & Revenues

Historic Earnings Reports

DXR Stock 12 Month Forecast

Average Price Target

$22.00

▲(93.32% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","23":"$23","10.25":"$10.25","14.5":"$14.5","18.75":"$18.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$22.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$22.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$22.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,10.25,14.5,18.75,23],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2022","6":"Sep<br/>2023","9":"Jan<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.45,10.415384615384614,11.38076923076923,12.346153846153845,13.311538461538461,14.276923076923076,15.24230769230769,16.207692307692305,17.173076923076923,18.138461538461538,19.103846153846153,20.06923076923077,21.034615384615385,{"y":22,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.45,10.415384615384614,11.38076923076923,12.346153846153845,13.311538461538461,14.276923076923076,15.24230769230769,16.207692307692305,17.173076923076923,18.138461538461538,19.103846153846153,20.06923076923077,21.034615384615385,{"y":22,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.45,10.415384615384614,11.38076923076923,12.346153846153845,13.311538461538461,14.276923076923076,15.24230769230769,16.207692307692305,17.173076923076923,18.138461538461538,19.103846153846153,20.06923076923077,21.034615384615385,{"y":22,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.72,"date":1619827200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.79,"date":1630454400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.72,"date":1646092800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.7,"date":1659312000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.25,"date":1677628800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.3,"date":1682899200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.7,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.89,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.45,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.69,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.56,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.14,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.45,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >